1Zhou X,Dere J,Zhu X,et al.Anxiety symptom presentations in Han Chinese and Euro-Canadian outpatients:is distress always somatized in China?[J].J Affect Disord,2011,135(1-3):111-114.
5[2]Angst J, Gamma A, Sellaro R, etc. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord,2002,72(2): 125
6Matteo Balestrieri,Ciulia Bisoffi,Miehele Tansella,et al.Identification of depression by medical and surgical general hospital physicians[J].General Hospital Psychiatry,2002,24:4-11.
7Marsden CA.The neuropharmacology of serotordn in the central nervous system[M].IN:feigner JP.Boyer WF.eds.Sclective Serotonin Re-uptake Inhibitom.Chiehester:John Wiley,1991,11-35.
8Shigeru M,Seizabum A.Differential effect s of milnaeipran,fluvoxamine and paroxetine for inhibited and agitated depression[J].European Psychiatry,2004,19:450-451.
9Donea MS,Nela P,Marina S,et al.The effects of paroxetine and tianeptine on peripheral makers in major depression[J].Progress in Neuro-psychopharmacology & Biological psychiatry,2002,26:1235-1243.
10Lysiard RB,Bobes J.Therapeutic advances:peroxetine for the treatment of social anxiety disorder[J].Depression Anxiety,2000,11:99-104.
